HONG KONG – Aiming to address a perceived disparity in the quality of manufacturing of drugs for the China market, the CFDA is ramping up its focus on offshore drug manufacturers. The regulator last year stepped up the number of overseas good manufacturing practice (GMP) inspections it carried out, while domestically, it put more of the onus on companies to police themselves.
HONG KONG – Aiming to address a perceived disparity in the quality of manufacturing of drugs for the China market, the CFDA is ramping up its focus on offshore drug manufacturers. The regulator last year stepped up the number of overseas good manufacturing practice (GMP) inspections it carried out, while domestically, it put more of the onus on companies to police themselves.
HONG KONG – Although the government has set its sights on advancing personalized medicine in China, most of the existing gene-related technologies are still of foreign origin, so are some of the leading companies operating here. The question at the moment is whether development of precision medicine in the country is a domestic or foreign affair? And where will the huge amount of government funding in the space go?
HONG KONG – China's Frontier Biotechnologies Co. Ltd. achieved positive results in a phase III study for the world's first injectable long-acting HIV drug. The weekly dose drug is targeted at Chinese patients via local development and manufacturing.
HONG KONG – Although the government has set its sights on advancing personalized medicine in China, most of the existing gene-related technologies are still of foreign origin, so are some of the leading companies operating here. The question at the moment is whether development of precision medicine in the country is a domestic or foreign affair? And where will the huge amount of government funding in the space go?
HONG KONG – Swiss pharmaceutical giant Novartis AG has officially launched its third global R&D hub, this one in China, where spirited debate over whether the country has true innovation or not is a daily occurrence.
HONG KONG – China's Frontier Biotechnologies Co. Ltd. achieved positive results in a phase III study for the world's first injectable long-acting HIV drug. The weekly dose drug is targeted at Chinese patients via local development and manufacturing.
HONG KONG – Swiss pharmaceutical giant Novartis AG has officially launched its third global R&D hub, this one in China, where spirited debate over whether the country has true innovation or not is a daily occurrence.
HONG KONG – Data infrastructure building has started quickly after China’s government announced plans to pour billions into the development of precision medicines. A group of leading companies in cloud computing, medical services and genomics have come together to provide the country with a platform essential to the future bloom of precision medicine in the country.
